Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07315373) titled 'Optimal Dose of Zanubrutinib to Treat Adult Immune Thrombocytopenia' on Dec. 18, 2025.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).
Primary Sponsor: Peking University People's Hospital
Condition:
Immune Thrombocytopenia
Intervention:
Drug: Zanubrutinib 80mg/d
Drug: High dose dexamethasone
Drug: Zanubrutinib 160mg/d
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: December 25, 2025
Target Sample Size: 60
To know more, visit https://clinicaltrials.gov/st...